0
Editorial |

Pneumonia in Older Adults: Title and subTitle BreakReversing the Trend

Thomas M. File, MD; James S. Tan, MD
[+] Author Affiliations

Author Affiliations: Section of Infectious Disease, Department of Internal Medicine, Northeastern Ohio Universities College of Medicine, Rootstown; and Department of Internal Medicine, Summa Health System, Akron, Ohio.

More Author Information
JAMA. 2005;294(21):2760-2763. doi:10.1001/jama.294.21.2760
Text Size: A A A
Published online

Community-acquired pneumonia is a common illness associated with significant morbidity and mortality,1 particularly for older adults and those with comorbid disease.2 - 3 An estimated 915 900 episodes of community-acquired pneumonia occur in adults aged 65 years or older each year in the United States and approximately 1 of every 20 persons aged 85 years and older will have a new occurrence yearly.4 Most of the hospitalizations and excess deaths due to community-acquired pneumonia occur in older adults, and most of the cost is for patients older than 65 years.5

To better meet the health care needs of older patients and potentially alleviate the economic burden on the health care system, it is imperative to understand the epidemiology of pneumonia in this group of patients. In this issue of JAMA, Fry and colleagues6 examined the trends according to age groups in hospitalizations for pneumonia by comparing National Hospital Discharge Survey data from 1988-1990 and 2000-2002. They found that hospitalization rates have increased among US adults aged 65 to 84 years. Although the hospitalization rate among persons aged 85 years or older did not increase significantly from 1988-1990 to 2000-2002, the rate was approximately twice that of adults aged 65 to 84 years.

In addition, the authors report that the proportion of elderly patients with comorbid chronic diseases also has increased. Such comorbidities increase the severity of pneumonia and adversely influence the outcome of patients. Because this increase in pneumonia hospitalizations represents substantial morbidity and mortality and is associated with increased health care costs, it is appropriate to consider whether this trend can be reduced. The study by Fry et al does not provide a solution, but it does suggest the need to explore various strategies to address the trend. Currently the best approach is to reduce susceptibility to infection by immunization and smoking cessation, as well as reducing comorbidities to the extent possible (such as better control of diabetes, congestive heart failure, and chronic obstructive pulmonary disease), and reducing malnutrition and risks for aspiration.

Vaccination is the mainstay for prevention of community-acquired pneumonia.7 Pneumococcal polysaccharide and inactivated influenza vaccines are recommended for all older adults and for younger persons with medical conditions that place them at high risk for pneumonia and its complications.7 - 8 The new live, attenuated influenza vaccine is recommended for healthy persons (those without a comorbid illness that could place them at higher risk of pneumonia and who are not in contact with high-risk persons) aged 5 to 49 years.8 The efficacy of the pneumococcal polysaccharide vaccine has been documented for prevention of invasive infection (eg, bacteremia) among younger and older adults with certain chronic medical conditions.7 The vaccine reduces invasive pneumococcal disease among persons aged 65 years or older by a relative 44% to 75%. Efficacy decreases with advancing age,9 - 10 and although one randomized clinical trial suggested some protection against pneumococcal pneumonia among high-risk elderly persons,11 other trials did not demonstrate efficacy against lower respiratory tract infection without bacteremia.12 - 13 The 7-valent pneumococcal conjugate vaccine is currently licensed only for use in children aged 2 to 59 months but has reduced disease in adults by lessening transmission from children.14

The effectiveness of influenza vaccines depends on host factors and on the degree of match between circulating viral strains and vaccine strains. Some recent reports suggest that vaccination has had a modest effect in reducing mortality or influenza-related complications in elderly persons.15 - 16 However, generalizing these studies to other populations is difficult because of variations in methods and measured outcomes (ie, all-cause mortality vs confirmed influenza infection vs influenza-like illness). Furthermore, a recent meta-analysis and review of controlled trials of community-dwelling elderly persons found that the inactivated vaccine is approximately 25% to 50% effective in reducing hospitalizations for pneumonia or influenza.17 - 18 In addition, economic studies of influenza vaccination of persons aged 65 years or older have shown overall societal cost savings.19

The effect of influenza vaccine seems to have additional benefits besides simply protecting against direct infection. A large observational study of adults aged 65 years or older showed that vaccination against influenza was associated with a relative reduction in the risk of hospitalization for cardiac disease (19% reduction), cerebrovascular disease (16%-23% reduction), and pneumonia or influenza (29%-32% reduction) and a relative reduction in the risk of death from all causes (48%-50% reduction).20

Although vaccines may not be as immunogenic in older patients,7 - 10 clinicians should adhere to recommendations to vaccinate all eligible elderly individuals with both vaccines. The 2 vaccines appear to work additively. Streptococcus pneumoniae is the most common cause of bacterial pneumonia after a respiratory virus infection and recent data suggest that the use of pneumococcal vaccine reduces the burden of viral pneumonia that may be caused by viruses other than influenza.21 In one study in Sweden, the use of either pneumococcal or influenza vaccine alone did not significantly reduce the occurrence of influenza or invasive pneumococcal pneumonia, but the combination of the 2 vaccines was associated with a significant decrease in hospital admissions for influenza or pneumonia.22

While influenza and pneumococcal polysaccharide vaccines are recommended for individuals aged 65 years or older and those with comorbidities, many individuals have not received them. A 2003 US survey indicated that among individuals aged 65 years or older, coverage was only 69.9% for influenza and 64.2% for pneumococcal vaccine.23 Studies of vaccine delivery strategies indicate that the use of standing orders is the best way to improve vaccination coverage in office, hospital, or long-term care settings.24 Hospitalization of at-risk patients represents an underused opportunity to assess vaccination status and provide recommended immunization.25 Influenza and pneumococcal vaccines can be given at the same time in different arms. The vaccines should be provided either during hospitalization or at a follow-up office visit.

As Fry et al point out, new strategies for preventive vaccines are necessary. The development of more potent vaccines could potentially further reduce complications in elderly persons. It will be important to determine whether new recommendations for influenza vaccination of children will have a similar effect of reducing the disease burden in older adults as it has with the use of the conjugate pneumococcal vaccine for invasive pneumococcal disease. One study in Japan showed that mortality in elderly individuals significantly decreased as more schoolchildren were vaccinated for influenza.26 In addition, the role of vaccines for other respiratory viruses (eg, respiratory syncytial virus, parainfluenza, adenovirus, metapneumovirus) needs to be explored.

Chemoprophylaxis can be used as an adjunct to vaccination for prevention and control of influenza. Chemoprophylaxis may be useful for those who have household exposure to influenza, who live or work in institutions with an influenza outbreak, or who are at high risk for influenza complications in the setting of a community outbreak.8 Chemoprophylaxis also may be useful for persons with contraindications to influenza vaccine or as an adjunct to vaccination for those who may not respond well to influenza vaccine (eg, persons with human immunodeficiency virus).8 Amantadine and rimantadine have indications approved by the Food and Drug Administration for treatment and chemoprophylaxis of influenza A infection. However, some clinicians may prefer to use oseltamivir because it is indicated for prevention and treatment of both influenza A and B.8

In addition to immunization, another consideration to potentially lessen the burden of community-acquired pneumonia in older adults may be directed at reducing the impact of comorbid conditions. Risk factors associated with community-acquired pneumonia in elderly patients include chronic obstructive pulmonary disease, chronic heart failure, diabetes, malnutrition, and swallowing disorders, which increase the risk of aspiration.2 - 3 ,27 - 30 In addition to predisposing to community-acquired pneumonia, these conditions significantly worsen the outcome of pneumonia among older adults.27 While the effect of comorbid conditions on pneumonia is well established, whether optimally controlling these conditions will reduce the burden of pneumonia in elderly persons is unclear. Will interventions such as more intensive treatment of diabetes, chronic obstructive pulmonary disease, and congestive heart failure; supplementing nutritional deficiencies; or evaluation of risk factors for aspiration reduce the predisposition or severity of pneumonia? Previous studies have shown that hyperglycemia at the time of hospital admission adversely affects patients with a wide variety of clinical illnesses, including community-acquired pneumonia.31 However, no prospectively controlled trials have assessed the effect of more rigorous control of blood glucose levels, or other comorbidities, on the incidence and outcome of pneumonia.

Because aspiration of microorganisms in oropharyngeal secretions is a major cause of pneumonia in elderly persons and swallowing disorders are the major risk factor for aspiration, clinical assessment of oropharyngeal hygiene and swallowing problems may be beneficial.29 Evaluation for swallowing disorders, which are common after cerebral infarction, may be performed by observation of oral movement and swallowing of various foods. Potential approaches to reduce aspiration in such patients include dietary modification and compensatory swallowing techniques,29 although we are unaware of any controlled studies that have shown a reduction in associated pneumonia. Furthermore, because poor oral/dental hygiene is associated with increased bacterial colonization of oral secretions and of dental plaque,32 attempts to improve dental hygiene may reduce the infectious consequences of aspiration. The relatively easy act of daily teeth brushing may help to prevent pneumonia, but carefully conducted studies are needed. In addition to potentially reducing dental plaque, one study showed that the simple procedure of daily brushing stimulates sensory nerves that improved the swallowing reflex in elderly patients in nursing homes.33

Until carefully controlled studies of these interventions have been conducted, definitive recommendations are not possible. Such studies should assess multiple outcomes rather than pneumonia alone because a single disease-oriented study or guideline may not recognize potentially undesirable consequences of the intervention for coexisting conditions.34 - 35 Randomized clinical trials need to be designed to account for the variable effect of multiple comorbidities. However, because pneumonia is one of the most common reasons for hospitalization and is associated with significant morbidity and mortality, it is vital to conduct such studies.

One intervention for comorbid illness for which no further study is needed is smoking cessation. In one study, nearly one third of pneumonia episodes in senior adult smokers and 4% of pneumonia events population-wide could be attributed to smoking.4 Smoking is also associated with a substantial risk of pneumococcal bacteremia; one study showed that smoking was the strongest risk factor for invasive pneumococcal disease in immunocompetent nonelderly adults.36 Counseling patients to quit smoking and providing them with materials to assist with smoking cessation are essential.37 - 38 In summary, numerous risk factors and underlying conditions affect the susceptibility to and prognosis of pneumonia in elderly individuals.

Clinicians can intervene to modify some of the associated risk factors for pneumonia in older adults. Administration of preventive vaccines, counseling about smoking cessation, stabilization of underlying conditions, and promotion of appropriate nutrition may help to reduce the risk of community-acquired pneumonia and thereby promote longer and healthier lives for older adults.

AUTHOR INFORMATION

Corresponding Author: Thomas M. File, Jr, MD, 75 Arch St, Suite 105, Akron, OH 44304 (filet@summa-health.org).

Financial Disclosures: Dr File has received research funding within the last 5 years from Abbott, Arpida AG, AstraZeneca, Bristol-Myers Squibb, Bayer, Binax Incorporated, Cubist, Genzyme, GlaxoSmithKline, Ortho-McNeil, Oscient, Pfizer, Sanofi-Aventis, Theravance, and Wyeth; has been a consultant to Sanofi-Aventis, Bayer, GlaxoSmithKline, Ortho-McNeil, Merck, Oscient, Pfizer, and Wyeth; and served on the speakers’ bureau for Abbott, Sanofi-Aventis, GlaxoSmithKline, Merck, Ortho McNeil, Oscient, Pfizer, Schering Plough, and Wyeth. Dr Tan has received research funding within the last 5 years from Abbott, Arpida AG, AstraZeneca, Bayer, Binax Incorporated, Bristol-Myers Squibb, Cubist, Genzyme, GlaxoSmithKline, Ortho-McNeil, Oscient, Pfizer, Sanofi-Aventis, Theravance, and Wyeth; has been a consultant to Sanofi-Aventis, Bayer, GlaxoSmithKline, Ortho-McNeil, Merck, Oscient, Pfizer, and Wyeth; and served on the speakers’ bureau for Pfizer, Sanofi-Aventis, Merck, and Wyeth.

Editorials represent the opinions of the authors and JAMA and not those of the American Medical Association.

File TM Jr. Community-acquired pneumonia.  Lancet. 2003;3621991-2001
PubMed
Loeb M. Epidemiology of community- and nursing home-acquired pneumoniae in older adults.  Expert Rev Anti Infect Ther. 2005;3263-279
PubMed
Janssens JP. Pneumonia in the elderly population.  Curr Opin Pulm Med. 2005;11226-230
PubMed
Jackson ML, Neuzil KM, Thompson WW.  et al.  The burden of community-acquired pneumonia in seniors.  Clin Infect Dis. 2004;391642-1650
PubMed
Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. The cost of treating community-acquired pneumonia.  Clin Ther. 1998;20820-837
PubMed
Fry AM, Shay DK, Holman RC, Curns AT, Anderson LJ. Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988-2002.  JAMA. 2005;2942712-2719
Whitney CG, Harper SA. Lower respiratory tract infections: prevention using vaccines.  Infect Dis Clin North Am. 2004;18899-917
PubMed
 Prevention and control of influenza.  MMWR Morb Mortal Wkly Rep. 2005;541-40
PubMed
Butler JC, Breiman RF, Campbell JF.  et al.  Polysaccharide pneumococcal vaccine efficacy.  JAMA. 1993;2701826-1831
PubMed
Jackson LA, Neuzil KM, Yu O.  et al.  Effectiveness of pneumococcal polysaccharide vaccine in older adults.  N Engl J Med. 2003;3481747-1755
PubMed
Koivula I, Stén M, Leinonen M, Mäkelä PH. Clinical efficacy of pneumococcal vaccine in the elderly.  Am J Med. 1997;103281-290
PubMed
Simberkoff MS, Cross AP, Al-Ibrahim M.  et al.  Efficacy of pneumococcal vaccine in high-risk patients.  N Engl J Med. 1986;3151318-1327
PubMed
Örtqvist Å, Hedlund J, Burman LÅ.  et al.  Randomized trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-age and elderly people.  Lancet. 1998;351399-403
PubMed
Whitney CG, Farley MM, Hadler J.  et al.  Decline in invasive pneumococcal disease following the introduction of protein-polysaccharide conjugate vaccine.  N Engl J Med. 2003;3481737-1746
PubMed
Simonsen L, Reichert TA, Viboud C.  et al.  Impact of influenza vaccination on seasonal mortality in the US elderly population.  Arch Intern Med. 2005;165265-272
PubMed
Jefferson T, Rivetti A, Riden M, DiPretrantonj C, Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review.  Lancet. 2005;3661165-1174
Vu T, Farish S, Jenkins M, Kelly H. A meta-analysis of effectiveness of influenza vaccine in persons ages 65 years and over living in the community.  Vaccine. 2002;201831-1836
PubMed
Nichol KL. Influenza vaccination in the elderly.  Drugs Aging. 2005;22495-515
PubMed
Nichol KL, Wuorenma J, von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens.  Arch Intern Med. 1998;1581769-1776
PubMed
Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwan M. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly.  N Engl J Med. 2003;3481322-1332
PubMed
Madhi SA, Klugman KP.Vaccine Trialist Group.  A role for Streptococcus pneumoniae in virus-associated pneumonia.  Nat Med. 2004;10811-813
PubMed
Christenson B, Hedlund J, Lundbergh P, Ortqvist A. Additive preventive effect of influenza and pneumococcal vaccines in elderly persons.  Eur Respir J. 2004;23363-368
PubMed
 Influenza and pneumococcal vaccination coverage among persons age ≥65 years and persons aged 18-64 years with diabetes and asthma—United States, 2003.  MMWR Morb Mortal Wkly Rep. 2004;531007-1012
PubMed
 Use of standing orders programs to increase adult vaccination rates.  MMWR Recomm Rep. 2000;49((RR-1)):15-16
PubMed
Bratzler DW, Houck PM, Jiang H.  et al.  Failure to vaccinate Medicare inpatients: a missed opportunity.  Arch Intern Med. 2002;1622349-2356
PubMed
Reichert TA, Sugaya N, Fedson DS, Glezen WP, Simonsen L, Tashiro M. The Japanese experience with vaccinating schoolchildren against influenza.  N Engl J Med. 2001;344889-896
PubMed
Riquelme R, Torres A, El-Ebiary M.  et al.  Community-acquired pneumonia in the elderly.  Am J Respir Crit Care Med. 1996;1541450-1455
PubMed
Kaplan V, Angus DC, Griffin MF.  et al.  Hospitalized community-acquired pneumonia in the elderly.  Am J Respir Crit Care Med. 2002;165766-772
PubMed
Kikawada M, Iwamoto T, Takasaki M. Aspiration and infection in the elderly: epidemiology, diagnosis and management.  Drugs Aging. 2005;22115-130
PubMed
Muller LMAJ, Gorter KJ, Jak E. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus.  Clin Infect Dis. 2005;41281-288
PubMed
McAlister FA, Majumdar SR, Blitz S, Rowe BH, Romney J, Marrie TJ. The relation between hyperglycemia and outcome in 2,471 patients admitted to the hospital with community-acquired pneumonia.  Diabetes Care. 2005;28810-815
PubMed
El-Solh AA, Pietrantoni C, Bhat A.  et al.  Colonization of dental plaques.  Chest. 2004;1261575-1582
PubMed
Yoshino A, Ebihara T, Ebihara S.  et al.  Daily oral care and risk factors for pneumonia in older patients in nursing homes.  JAMA. 2001;2862235-2236
PubMed
Boyd CM, Darer J, Boult C.  et al.  Clinical practice guidelines and quality of care of older patients with multiple comorbid diseases.  JAMA. 2005;294716-724
PubMed
O’Connor PJ. Adding value to evidence-based clinical guidelines.  JAMA. 2005;294741-743
PubMed
Nuorti JP, Butlser JC, Farley MM.  et al.  Cigarette smoking and invasive pneumococcal disease.  N Engl J Med. 2000;342681-689
PubMed
US Department of Health and Human Services.  Tobacco cessation: you can quit smoking now! Available at: http://www.surgeongeneral.gov/tobacco/. Accessed October 12, 2005
Centers for Disease Control and Prevention.  Tobacco information and prevention. Available at: http://www.cdc.gov/tobacco/. Accessed October 12, 2005

First Page Preview

First page PDF preview

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

File TM Jr. Community-acquired pneumonia.  Lancet. 2003;3621991-2001
PubMed
Loeb M. Epidemiology of community- and nursing home-acquired pneumoniae in older adults.  Expert Rev Anti Infect Ther. 2005;3263-279
PubMed
Janssens JP. Pneumonia in the elderly population.  Curr Opin Pulm Med. 2005;11226-230
PubMed
Jackson ML, Neuzil KM, Thompson WW.  et al.  The burden of community-acquired pneumonia in seniors.  Clin Infect Dis. 2004;391642-1650
PubMed
Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. The cost of treating community-acquired pneumonia.  Clin Ther. 1998;20820-837
PubMed
Fry AM, Shay DK, Holman RC, Curns AT, Anderson LJ. Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988-2002.  JAMA. 2005;2942712-2719
Whitney CG, Harper SA. Lower respiratory tract infections: prevention using vaccines.  Infect Dis Clin North Am. 2004;18899-917
PubMed
 Prevention and control of influenza.  MMWR Morb Mortal Wkly Rep. 2005;541-40
PubMed
Butler JC, Breiman RF, Campbell JF.  et al.  Polysaccharide pneumococcal vaccine efficacy.  JAMA. 1993;2701826-1831
PubMed
Jackson LA, Neuzil KM, Yu O.  et al.  Effectiveness of pneumococcal polysaccharide vaccine in older adults.  N Engl J Med. 2003;3481747-1755
PubMed
Koivula I, Stén M, Leinonen M, Mäkelä PH. Clinical efficacy of pneumococcal vaccine in the elderly.  Am J Med. 1997;103281-290
PubMed
Simberkoff MS, Cross AP, Al-Ibrahim M.  et al.  Efficacy of pneumococcal vaccine in high-risk patients.  N Engl J Med. 1986;3151318-1327
PubMed
Örtqvist Å, Hedlund J, Burman LÅ.  et al.  Randomized trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-age and elderly people.  Lancet. 1998;351399-403
PubMed
Whitney CG, Farley MM, Hadler J.  et al.  Decline in invasive pneumococcal disease following the introduction of protein-polysaccharide conjugate vaccine.  N Engl J Med. 2003;3481737-1746
PubMed
Simonsen L, Reichert TA, Viboud C.  et al.  Impact of influenza vaccination on seasonal mortality in the US elderly population.  Arch Intern Med. 2005;165265-272
PubMed
Jefferson T, Rivetti A, Riden M, DiPretrantonj C, Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review.  Lancet. 2005;3661165-1174
Vu T, Farish S, Jenkins M, Kelly H. A meta-analysis of effectiveness of influenza vaccine in persons ages 65 years and over living in the community.  Vaccine. 2002;201831-1836
PubMed
Nichol KL. Influenza vaccination in the elderly.  Drugs Aging. 2005;22495-515
PubMed
Nichol KL, Wuorenma J, von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens.  Arch Intern Med. 1998;1581769-1776
PubMed
Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwan M. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly.  N Engl J Med. 2003;3481322-1332
PubMed
Madhi SA, Klugman KP.Vaccine Trialist Group.  A role for Streptococcus pneumoniae in virus-associated pneumonia.  Nat Med. 2004;10811-813
PubMed
Christenson B, Hedlund J, Lundbergh P, Ortqvist A. Additive preventive effect of influenza and pneumococcal vaccines in elderly persons.  Eur Respir J. 2004;23363-368
PubMed
 Influenza and pneumococcal vaccination coverage among persons age ≥65 years and persons aged 18-64 years with diabetes and asthma—United States, 2003.  MMWR Morb Mortal Wkly Rep. 2004;531007-1012
PubMed
 Use of standing orders programs to increase adult vaccination rates.  MMWR Recomm Rep. 2000;49((RR-1)):15-16
PubMed
Bratzler DW, Houck PM, Jiang H.  et al.  Failure to vaccinate Medicare inpatients: a missed opportunity.  Arch Intern Med. 2002;1622349-2356
PubMed
Reichert TA, Sugaya N, Fedson DS, Glezen WP, Simonsen L, Tashiro M. The Japanese experience with vaccinating schoolchildren against influenza.  N Engl J Med. 2001;344889-896
PubMed
Riquelme R, Torres A, El-Ebiary M.  et al.  Community-acquired pneumonia in the elderly.  Am J Respir Crit Care Med. 1996;1541450-1455
PubMed
Kaplan V, Angus DC, Griffin MF.  et al.  Hospitalized community-acquired pneumonia in the elderly.  Am J Respir Crit Care Med. 2002;165766-772
PubMed
Kikawada M, Iwamoto T, Takasaki M. Aspiration and infection in the elderly: epidemiology, diagnosis and management.  Drugs Aging. 2005;22115-130
PubMed
Muller LMAJ, Gorter KJ, Jak E. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus.  Clin Infect Dis. 2005;41281-288
PubMed
McAlister FA, Majumdar SR, Blitz S, Rowe BH, Romney J, Marrie TJ. The relation between hyperglycemia and outcome in 2,471 patients admitted to the hospital with community-acquired pneumonia.  Diabetes Care. 2005;28810-815
PubMed
El-Solh AA, Pietrantoni C, Bhat A.  et al.  Colonization of dental plaques.  Chest. 2004;1261575-1582
PubMed
Yoshino A, Ebihara T, Ebihara S.  et al.  Daily oral care and risk factors for pneumonia in older patients in nursing homes.  JAMA. 2001;2862235-2236
PubMed
Boyd CM, Darer J, Boult C.  et al.  Clinical practice guidelines and quality of care of older patients with multiple comorbid diseases.  JAMA. 2005;294716-724
PubMed
O’Connor PJ. Adding value to evidence-based clinical guidelines.  JAMA. 2005;294741-743
PubMed
Nuorti JP, Butlser JC, Farley MM.  et al.  Cigarette smoking and invasive pneumococcal disease.  N Engl J Med. 2000;342681-689
PubMed
US Department of Health and Human Services.  Tobacco cessation: you can quit smoking now! Available at: http://www.surgeongeneral.gov/tobacco/. Accessed October 12, 2005
Centers for Disease Control and Prevention.  Tobacco information and prevention. Available at: http://www.cdc.gov/tobacco/. Accessed October 12, 2005
CME Course for:


You need to register in order to view this quiz.


To understand the clinical management of acute heart failure syndromes.
Accreditation Information The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
To view and print your certificate and access a summary of your CME courses go to My CME.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles
JAMAevidence.com